Integer (NYSE:ITGR) issued an update on its FY19 earnings guidance on Thursday morning. The company provided earnings per share guidance of $4.25-4.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.29. The company issued revenue guidance of $1.265-1.280 billion, compared to the consensus revenue estimate of $1.28 billion.
Shares of NYSE ITGR opened at $87.53 on Thursday. Integer has a 12-month low of $67.72 and a 12-month high of $92.61. The firm has a market cap of $2.81 billion, a P/E ratio of 23.03 and a beta of 0.95. The company has a current ratio of 2.55, a quick ratio of 1.49 and a debt-to-equity ratio of 0.84. The firm has a fifty day moving average of $82.57.
Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.20. The firm had revenue of $314.70 million during the quarter, compared to the consensus estimate of $302.29 million. Integer had a return on equity of 13.37% and a net margin of 14.67%. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 EPS. As a group, equities analysts predict that Integer will post 4.3 earnings per share for the current fiscal year.
In related news, Director James F. Hinrichs purchased 3,750 shares of Integer stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average price of $68.47 per share, with a total value of $256,762.50. Following the completion of the transaction, the director now owns 6,549 shares of the company’s stock, valued at approximately $448,410.03. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 2.24% of the company’s stock.
Integer Company Profile
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
Featured Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.